Affinivax is developing a pipeline of next-generation vaccines, based on its proprietary technology platform, the Multiple Antigen Presenting System (MAPS). In stark contrast with traditional conjugation vaccine strategies, the non-covalent, high-affinity binding approach with MAPS enables the generation of a robust immune response to both the polysaccharide and protein antigens in the vaccine, which provides much broader protection against the most-invasive bacterial pathogens.
Affinivax is applying its novel MAPS platform to develop vaccines designed to provide significantly more protection than existing vaccines, as well as vaccines against infectious diseases for which there are no effective immunization strategies today. Its lead MAPS vaccine program is targeting Streptococcus pneumoniae, which remains a major cause of morbidity and mortality in the U.S. and around the world. Its second program is targeting bacterial nosocomial infections (also referred to as health-care associated infections), which is a significant global health concern in medical facilities, and for which there are no vaccines available today for prevention.
- Richard Malley, MD Scientific Founder
- Steven B. Brugger President & CEO
- Kamran Tavangar, PhD Chief Operating Officer